Day: September 10, 2020

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.59669-59-9,3-(tert-Butyl)isoxazol-5-amine,as a common compound, the synthetic route is as follows.

59669-59-9, Step 6: Synthesis of compound B-7Activation of 55.9 g (22.3 mmol) of compound B-6 is achieved by treatment with thionyl chloride (600 mL) at 60 ¡ãC for 3 h. The reaction mixture is cooled to room temperature and excess thionyl chloride is removed under reduced pressure.The crude acid chloride is dissolved in DCM (400 mL) and added to a solution of 31.3 g (22.3 mmol) of 3-tert-Butyl-isoxazol-5-ylamine and N,N-diisopropylethylamine (194 mL) in DCM (250mL). The reaction is stirred at room temperature for 16 h. The reaction mixture is diluted with DCM (1350 mL) and washed with saturated aqueous NaHCC>3 solution (1000 mL). The organic layer is dried over Na2S04, filtered and the filtrate is concentrated under reduced pressure. The crude product is purified by dry-flash column chromatography (2 kg silica, eluent: DCM, 0-20percent ethyl acetate). The resulting solid is recrystallised from isopropanol/heptanes (1/1. 2 L), then dried under reduced pressure to afford 80 g of compound B-7 as an off-white powder. Yield 96percent; ES-MS: m/z 373 [M+H]; XH NMR (360 MHz, CHLOROFORM-d) delta ppm 1.35 (9 H, s), 1.41 – 1.55 (2 H, m), 1.74 (6 H, s), 1.82 – 1.91 (2 H, m), 2.29 – 2.52 (1 H, m), 2.92 (2 H, d, 7=6.58 Hz), 3.34 – 3.49 (2 H, m), 3.88 – 4.00 (2 H, m), 6.30 (1 H, s), 9.38 (1 H, s).

As the paragraph descriping shows that 59669-59-9 is playing an increasingly important role.

Reference£º
Patent; BOEHRINGER INGELHEIM INTERNATIONAL GMBH; HICKEY, Eugene Richard; RIETHER, Doris; ERMANN, Monika; WO2012/12307; (2012); A1;,
Isoxazole – Wikipedia
Isoxazole | C3H3NO – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.14441-90-8,5-Phenylisoxazole-3-carboxylic acid,as a common compound, the synthetic route is as follows.

General procedure: Thionyl chloride (1.2 mL) was added at 0 C to the 3-phenylisoxazole-5-carboxylic acid 13 or the 5-phenylisoxazole-3-carboxylic acid 14 or the 5-(4-chlorophenyl)isoxazole-3-carboxylic acid 15 or the 3-(4-methylphenyl)isoxazole-5-carboxylic acid 16 (0.3 g, 1.58 mmol). The obtained suspension was stirred and heated at reflux for 16 h and then cooled at 0 C. At this temperature, a new addition of thionyl chloride (1.2 mL) was followed by another heating at reflux for 2 h. The reaction mixture was cooled at room temperature and the thionyl chloride excess was evaporated to dryness in vacuo. Anhydrous THF (2 mL) was added to the crude product. To the resulting solution, cooled at -5 C, was added dropwise a solution of appropriate amine (3.16 mmol) in dry THF (2 mL). The reaction mixture was stirred at room temperature for ca. 90 min (TLC, petroleum ether/ethyl acetate) and then the solid mass was filtered off and washed with THF. The filtrate was evaporated to dryness; the residue was treated with saturated sodium bicarbonate solution (20 mL) and extracted with dichloromethane (3¡Á15 mL). The combined organic phases were dried (Na2SO4) and evaporated to dryness to give the crude product, purified by flash-chromatography to give the desired amide.

14441-90-8, 14441-90-8 5-Phenylisoxazole-3-carboxylic acid 151916, aIsoxazoles compound, is more and more widely used in various fields.

Reference£º
Article; Cosimelli, Barbara; Simorini, Francesca; Taliani, Sabrina; La Motta, Concettina; Da Settimo, Federico; Severi, Elda; Greco, Giovanni; Novellino, Ettore; Costa, Barbara; Da Pozzo, Eleonora; Bendinelli, Sara; Martini, Claudia; European Journal of Medicinal Chemistry; vol. 46; 9; (2011); p. 4506 – 4520;,
Isoxazole – Wikipedia
Isoxazole | C3H3NO – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.36958-61-9,5-(Bromomethyl)-3-methylisoxazole,as a common compound, the synthetic route is as follows.

Example 13 (5RS)-2-[(3-Methyl-1,2-oxazol-5-yl)methyl]-5-(pyrrolidin-1-ylcarbonyl)-5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one (Racemate) (5RS)-5-(Pyrrolidin-1-ylcarbonyl)-5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one (racemate) (40.0 mg, 169 mumol) was initially charged in acetonitrile (2.0 ml). Caesium carbonate (82.7 mg, 254 mumol) and 5-(bromomethyl)-3-methyl-1,2-oxazole (32.8 mg, 186 mumol) were subsequently added. After stirring at room temperature for 2 days, the reaction mixture was admixed with water and ethyl acetate. The organic phase was removed and the aqueous phase was extracted three times with ethyl acetate. The combined organic phases were washed with saturated aqueous sodium chloride solution, dried over sodium sulphate and filtered, and the filtrate was concentrated. 18.6 mg (33% of theory) of the title compound were obtained. LC-MS (Method 3): Rt=0.89 min; MS (ESIpos): m/z=332 [M+H]+ 1H-NMR (400 MHz, DMSO-d6) delta [ppm]: -0.008 (0.87), 0.008 (0.76), 1.686 (0.49), 1.709 (0.99), 1.720 (1.17), 1.732 (0.87), 1.753 (0.57), 1.772 (1.53), 1.789 (2.62), 1.806 (2.01), 1.822 (0.60), 1.892 (0.62), 1.909 (1.85), 1.925 (2.33), 1.942 (1.50), 1.959 (0.66), 1.972 (0.52), 1.983 (0.78), 1.995 (0.71), 2.004 (0.63), 2.014 (0.50), 2.019 (0.48), 2.030 (0.68), 2.039 (0.56), 2.046 (0.46), 2.055 (0.49), 2.201 (16.00), 2.215 (0.69), 2.417 (0.49), 2.523 (1.09), 2.565 (0.86), 2.580 (0.74), 2.590 (0.68), 2.602 (1.21), 2.615 (0.66), 2.643 (0.48), 3.242 (0.75), 3.254 (0.74), 3.271 (1.33), 3.288 (0.70), 3.322 (0.97), 3.339 (1.33), 3.351 (0.50), 3.357 (0.70), 3.369 (0.78), 3.454 (0.86), 3.462 (0.63), 3.471 (0.53), 3.479 (1.08), 3.496 (0.47), 3.589 (0.50), 3.606 (1.03), 3.614 (0.52), 3.623 (0.59), 3.631 (0.79), 3.703 (0.42), 4.495 (0.41), 4.510 (0.41), 4.723 (0.92), 4.732 (1.05), 4.738 (1.20), 4.747 (0.90), 4.940 (4.70), 4.982 (0.54), 6.223 (3.16).

36958-61-9, As the paragraph descriping shows that 36958-61-9 is playing an increasingly important role.

Reference£º
Patent; BAYER AKTIENGESELLSCHAFT; BAYER PHARMA AKTIENGESELLSCHAFT; BIBER, Nicole; BROCKSCHNIEDER, Damian; GERICKE, Kersten Matthias; KOeLLING, Florian; LUSTIG, Klemens; MEDING, Joerg; MEIER, Heinrich; NEUBAUER, Thomas; SCHAeFER, Martina; TIMMERMANN, Andreas; ZUBOV, Dmitry; TERJUNG, Carsten; LINDNER, Niels; BADOCK, Volker; MOOSMAYER, Dieter; MIYATAKE ONDOZABAL, Hideki; MOORE, Steven; SCHULZ, Alexander; (458 pag.)US2019/160048; (2019); A1;,
Isoxazole – Wikipedia
Isoxazole | C3H3NO – PubChem

3209-71-0, Isoxazole-3-carboxylic Acid is a Isoxazoles compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Compound 3 (24.0 g) and 16.17 g of isoxazole-3-carboxylic acid were suspended in 288 mL of acetone, 49.36 g of pyridine was added thereto and the suspension was cooled to -10C. 31.89 g of phosphorus oxychloride was poured into the suspension to react at 20 +/- 10C for about 30 minutes. The reaction mixture was cooled to 5C or below, 5.3 mL of water was added dropwise to the mixture at 20C, and 355 mL of water was poured therein. Then, 10% sodium hydroxide aqueous solution was added dropwise to the mixture until pH 4.5, and the mixture was stirred at 15 +/- 10C for about 2 hours to precipitate crystals. The crystallized slurry obtained was filtered, and the crystals were washed sequentially with 48 mL of 10% aqueous acetone, 192 mL of water, and 72 mL of 10% aqueous acetone, and dried in vacuo to afford Compound 4 (33.24 g, 91.4%).

3209-71-0, 3209-71-0 Isoxazole-3-carboxylic Acid 11286453, aIsoxazoles compound, is more and more widely used in various fields.

Reference£º
Patent; SHIONOGI & CO., LTD.; EP1408041; (2004); A1;,
Isoxazole – Wikipedia
Isoxazole | C3H3NO – PubChem

2510-36-3, 3,5-Dimethylisoxasole-4-carboxylic acid is a Isoxazoles compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

To a solution of 6-(5-aminomethyl-4-chloro-pyridin-3-yl)-1-methyl-3,4-dihydro-1H-quinolin-2-one hydrochloride (example 218, 0.05 g, 0.148 mmol) in dry DMF (1 mL) were added EDCI (0.034 g, 0.077 mmol), hydroxybenzotriazole (0.017 g, 0.077 mmol), Huenig’s base (0.057 g, 0.443 mmol) and 3,5-dimethyl-isoxazole-4-carboxylic acid (0.021 g, 0.148 mmol) and the resulting solution was stirred at room temperature for 2 h. The reaction mixture was diluted with EtOAc, poured into sat. NaHCO3 solution (10 mL) and extracted with EtOAc (2¡Á20 mL). Combined organics were dried over Na2SO4, filtered and evaporated to dryness. The residue was purified by silica gel flash chromatography eluting with a 0 to 5% MeOH-DCM gradient to give the title compound (0.03 g, 48%) as a colorless solid. MS: 425.4 (M+H+)., 2510-36-3

As the paragraph descriping shows that 2510-36-3 is playing an increasingly important role.

Reference£º
Patent; Aebi, Johannes; Amrein, Kurt; Hornsperger, Benoit; Knust, Henner; Kuhn, Bernd; Liu, Yongfu; Maerki, Hans P.; Mayweg, Alexander V.; Mohr, Peter; Tan, Xuefei; Zhou, Mingwei; US2013/72679; (2013); A1;,
Isoxazole – Wikipedia
Isoxazole | C3H3NO – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.123770-62-7,Ethyl 5-(hydroxymethyl)isoxazole-3-carboxylate,as a common compound, the synthetic route is as follows.

Reference Production Example 200 (0843) Ethyl 5-hydroxymethylisoxazole-3-carboxylate (0.72 g, 4.2 mmol) was dissolved in tetrahydrofuran (25 mL), and 1-fluoro-2-naphthylmethyl bromide (1.20 g, 5.0 mmol) and 18-crown-6 (0.11 g, 0.4 mmol) were added thereto. Sodium hydride (60% oil-based) (0.34 g, 8.4 mmol) was slowly added thereto at room temperature, and the mixture was stirred at room temperature overnight. Then, dilute hydrochloric acid was added thereto, and the mixture was extracted three times with ethyl acetate. The organic layer was washed with saturated saline water, dried over anhydrous sodium sulfate, and then concentrated under reduced pressure. The residue was dissolved in ethanol (10 mL), and an aqueous solution obtained by dissolving potassium hydroxide (1.40 g, 25 mmol) in water (5 mL) was added thereto at room temperature, and then the mixture was stirred at 80C for 3 hours. Water was added to the reaction mixture, and the mixture was concentrated under reduced pressure. Tert-butyl methyl ether was added to the concentrate, and the aqueous layer was fractionated. Dilute hydrochloric acid was added to the resulting aqueous layer, and the mixture was extracted three times with ethyl acetate. The organic layer was washed with saturated saline water, dried over anhydrous sodium sulfate, and then concentrated under reduced pressure to obtain 0.59 g of 5-(1-fluoro-2-naphthylmethoxymethyl)isoxazole-3-carboxylic acid represented by the following formula. The product was subjected to a next reaction without purification., 123770-62-7

As the paragraph descriping shows that 123770-62-7 is playing an increasingly important role.

Reference£º
Patent; Sumitomo Chemical Company, Limited; MITSUDERA, Hiromasa; AWASAGUCHI, Kenichiro; AWANO, Tomotsugu; UJIHARA, Kazuya; EP2952096; (2015); A1;,
Isoxazole – Wikipedia
Isoxazole | C3H3NO – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.21169-71-1,Isoxazole-5-carboxylic acid,as a common compound, the synthetic route is as follows.,21169-71-1

Part 2. Amide coupling. Crude 32 (TJF-5) was synthesized from amine intermediate 31 (21.5?mg, 0.05?mmol) and isoxazole-5-carboxylic acid (7.3?mg, 0.06?mmol) according to general method D. The crude material was dissolved in a minimal amount of DCM, loaded onto a 10?g silica gel column, and purified by flash chromatography (MeOH/DCM, 0-5%) to give 32 48 (9.1?mg) as a white solid in 16% yield over 2 steps. LC/MS tR?=?6.46?min (Characterization Method A); m/z?=?499.00 (M+H+), 521.00 (M+Na+), 498.25 (M – H+), 543.25 (M+formic acid adduct); 1H NMR (300?MHz, CDCl3) delta?=?8.32 (d, J?=?1.5?Hz, 1H), 7.30 (s, 1H), 7.33-7.21 (m, 1H), 6.96-6.82 (m, 4H), 6.46 (app t, J?=?5.6?Hz, 1H), 4.74 (dd, J?=?8.5?Hz, 1H), 4.44 (ddd, J?=?8.8, 20.8?Hz, 2H), 4.27 (t, J?=?7.6?Hz, 1H), 3.86 (s, 3H), 1.89-1.73 (m, 3H), 1.72-1.58 (m, 7H), 1.52-1.38 (m, 1H), 1.37-1.24 (m, 2H), 1.22-1.02 (m, 4H), 0.98-0.88 (m, 2H), 0.88-0.79 (m, 6H).

The synthetic route of 21169-71-1 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Gandhi, Disha M.; Majewski, Mark W.; Rosas, Ricardo; Kentala, Kaitlin; Foster, Trevor J.; Greve, Eric; Dockendorff, Chris; Bioorganic and Medicinal Chemistry; vol. 26; 9; (2018); p. 2514 – 2529;,
Isoxazole – Wikipedia
Isoxazole | C3H3NO – PubChem

54593-26-9, 3,5-Dimethyl-4-isoxazolecarbaldehyde is a Isoxazoles compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated,54593-26-9

Example 1: (2,4-Dichloro-3-phenylquinolin-6-yl)(3,5-dimethylisoxazol-4-yl)methanolTHF (5 mL) was added to a mixture of 6-bromo-2,4-dichloro-3-phenylquinoline (363 mg, 1.03 mmol, Intermediate 1 : step c) and 3,5-dimefhyiisoxazole-4-carbaldehyde (1 80 mg, 1.44 mmol) under a nitrogen atmosphere. The resulting colorless solution was cooled in a dry ice/acetone bath. n-BuLi (1.6 M in hexane, 0.77 mL, 1.23 mmol) was added dropwise and the mixture was stirred at -78 C for 30 minutes, then moved to an ice bath and stirred for 30 minutes. The reaction was quenched by addition of saturated aqueous NH4Cl and was diluted with water. The mixture was extracted three times with EtOAc. The organic phase was dried (Na2SO4), filtered, and concentrated to afford the crude title compound, 1H NMR (400 MHz, DMSO-d6) delta ppm 8.35 (s, 1H), 8.04 (d, J = 8.80 Hz, 1H), 7,74 (dd, J = 1.71 , 8.80 Hz, 1H), 7,48 – 7.62 (m, 3H), 7.35 – 7.48 (m, 2H), 6.25 (d, J = 4, 16 Hz, 1H), 5,99 (d, J = 3.42 Hz, 1H), 2.37 (s, 3H), 1 .99 (s, 3H); MS m/e 398.9 (M+H)+.

As the paragraph descriping shows that 54593-26-9 is playing an increasingly important role.

Reference£º
Patent; JANSSEN PHARMACEUTICA NV; LEONARD, Kristi, A.; BARBAY, Kent; EDWARDS, James, P.; KREUTTER, Kevin, D.; KUMMER, David, A.; MAHAROOF, Umar; NISHIMURA, Rachel; URBANSKI, Maud; VENKATESAN, Hariharan; WANG, Aihua; WOLIN, Ronald, L.; WOODS, Craig, R.; FOURIE, Anne; XUE, Xiaohua; CUMMINGS, Maxwell, D.; WO2015/57206; (2015); A1;,
Isoxazole – Wikipedia
Isoxazole | C3H3NO – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.3405-77-4,5-Methylisoxazole-3-carboxylic acid,as a common compound, the synthetic route is as follows.

Example 19b A mixture of the product of Example 19a (30 mg, 0.039 mmol), 5-methylisoxazole-3-carboxylic acid (5.0 mg, 0.039 mmol), N-ethyl-N-isopropylpropan-2-amine (15.2 mg, 0.118 mmol), and HATU (17.9 mg, 0.047 mmol) in dichloromethane (0.5 mL) was stirred at mom temperature for one hour and then evaporated. Purification of the crude material via reverse phase chromatography eluting with acetonitrile/water/TFA provided the title compound (18 mg, 53percent yield). MS (ESI): m/z=837.9[M+H].

3405-77-4, The synthetic route of 3405-77-4 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; AbbVie Inc.; Enanta Pharmaceuticals, Inc.; Ku, Yiyin; McDaniel, Keith F.; Chen, Hui-Ju; Shanley, Jason P.; Kempf, Dale J.; Grampovnik, David J.; Sun, Ying; Liu, Dong; Gai, Yonghua; Or, Yat Sun; Wagaw, Seble H.; Engstrom, Kenneth; Grieme, Tim; Sheikh, Ahmad; Mei, Jianzhang; (46 pag.)US9309279; (2016); B2;,
Isoxazole – Wikipedia
Isoxazole | C3H3NO – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.3209-71-0,Isoxazole-3-carboxylic Acid,as a common compound, the synthetic route is as follows.

Exam le 5b; (2R,6S,13aS,14aR,16aS,Z)-ethyl 2-(3-(l,l-difluoroethyl)quinoxalin-2-yloxy)-6-(isoxazole-3- carboxamido)-5,16-dioxo-l,2,3,5,6,7,8,9,10,l l,13a,14,14a,15,16,16a- hexadecahydrocyclopropa[e]pyrrolo[l,2-a][l,4]diazacyclopentadecine-14a-carboxylate; To (2R,6S,13aS,14aR,16aS,Z)-ethyl 6-amino-2-(3-(l,l-difluoroethyl)quinoxalin-2-yloxy)- 5,16-dioxo-l,2,3,5,6,7,8,9,10,l l,13a,14,14a,15,16,16a- hexadecahydrocyclopropa[e]pyrrolo[l,2-a][l,4]diazacyclopentadecine-14a-carboxylate, hydrochloric acid (585.7 mg, 0.941 mmol) was added isoxazole-3-carboxylic acid (128 mg, 1.132 mmol) and DMF (9.4 ml). The reaction mixture was cooled to 0 C, and pyridine(0.761 ml, 9.41 mmol) then HATU (537.5 mg, 1.414 mmol) were added. The solution was stirred at rt 16 h, and LC/MS showed a small amount of SM remained. More isoxazole-3- carboxylic acid (52.3 mg) pyridine (0.2 ml) and HATU (179 mg) were added. The reaction mixture was stirred for an additional 16 h and LC/MS showed completion. The reaction mixture was concentrated under reduced pressure, and the oil was dissolved indichloromethane (100 ml) and washed with HC1 (1 N, 2 x 15 ml) and Na2C03 (1 N, 4 x 20 ml). The combined Na2C03 layer was back-extracted with dichloromethane (2 x 10 ml). The organic layers were combined, dried (MgS04) and concentrated, and purified bychromatography (SNAP50, acetonitrile/CHCl3 = 0-17%) to provide the title compound 5b (577 mg, 0.847 mmol, 90 % yield).

3209-71-0, The synthetic route of 3209-71-0 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; ABBOTT LABORATORIES; ENANTA PHARMACEUTICALS, INC.; CHEN, Hui-ju; MCDANIEL, Keith, F.; GREEN, Brian, E.; SHANLEY, Jason, P.; KRUGER, Albert, W.; GANDARILLA, Jorge; WELCH, Dennie, S.; CINK, Russell, D.; GAI, Yonghua; WANG, Guoqiang; OR, Yat, Sun; WO2011/156337; (2011); A2;,
Isoxazole – Wikipedia
Isoxazole | C3H3NO – PubChem